Novelix promoters increase stake via warrant conversion
Novelix Pharmaceuticals disclosed on July 13, 2026, that its promoters increased their shareholding through the conversion of warrants into equity shares on July 9, 2026. The allotment was executed via a preferential offer basis under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Following the transaction, the total voting capital stands at 28,470,000 equity shares, with Srinidhi Fine Chemicals LLP, Nanhari Belide, Vupparapalli Chandrasekhar Reddy, and Neha Gattu acquiring shares valued at ₹4,20,00,000, ₹8,00,00,000, ₹15,50,00,000, and ₹2,00,00,000 respectively.

*this image is generated using AI for illustrative purposes only.
Novelix Pharmaceuticals disclosed on July 13, 2026, that its promoters and promoter group increased their shareholding through the conversion of warrants into equity shares. The allotment, which occurred on July 9, 2026, was executed via a preferential offer basis as required under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This adjustment significantly alters the capital structure and promoter stakes within the company.
The total voting capital of Novelix Pharmaceuticals stands at 28,470,000 equity shares following the transaction. The conversion involved multiple acquirers, including Srinidhi Fine Chemicals LLP, Nanhari Belide, Vupparapalli Chandrasekhar Reddy, and Neha Gattu. The disclosures were submitted to BSE Limited by Venkateshwarlu Pulluri, Whole-time Director, on behalf of the company.
Shareholding Changes
The table below details the specific changes in holdings for the key acquirers, reflecting the movement from pre-allotment to post-allotment positions.
| Acquirer | Holding Before Acquisition | % Before Acquisition | Holding After Acquisition | % After Acquisition |
|---|---|---|---|---|
| Srinidhi Fine Chemicals LLP | 7,902,000 | 33.07 % | 10,002,000 | 35.13 % |
| Vupparapalli Chandrasekhar Reddy | 2,130,733 | 8.92 % | 2,905,733 | 10.21 % |
| Nanhari Belide | 800,000 | 3.35 % | 1,200,000 | 4.21 % |
| Neha Gattu | 0 | 0.00 % | 100,000 | 0.35 % |
Srinidhi Fine Chemicals LLP acquired 2,100,000 shares at a value of ₹4,20,00,000, while Vupparapalli Chandrasekhar Reddy acquired 775,000 shares valued at ₹15,50,00,000. Nanhari Belide added 400,000 shares worth ₹8,00,00,000, and Neha Gattu acquired 100,000 shares valued at ₹2,00,00,000. The company confirmed that no trading in derivatives was conducted by these individuals during this period.
Historical Stock Returns for Trimurthi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.46% | -1.06% | -11.38% | +16.85% | +64.17% | +725.36% |
How will the increased promoter holding influence Novelix Pharmaceuticals' strategic decision-making and future capital allocation?
What are the potential market reactions to the dilution of public shareholding and the consolidation of promoter stakes?
Could this move signal upcoming expansion plans or acquisitions by the company given the fresh infusion of equity capital?
























